Balancing Speed and Risk to Meet an Aggressive Timeline
In this customer case study, we are focusing on our collaboration with Acticor Biotech, a spin-off of Inserm, the French National Institute of Health and Medical Research, which is advancing an innovative drug for the treatment of the acute phase of ischemic stroke.
Acticor selected MilliporeSigma’s BioReliance® End-to-End Solutions for process development and GMP manufacturing of a Fab fragment to support clinical trials. The project timeline allowed only 18 months to get from the cell line to clinical batch manufacturing. A strategic approach to risk management was leveraged to help meet an aggressive timeline.